Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal (Q39478177)

12 September 2017

title

Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal (English)

1 reference

12 September 2017

0 references

1 reference

1 reference

1 reference

1 reference

0 references

Elamin H Elbasha

1 reference

12 September 2017

Jagpreet Chhatwal

series ordinal

1 reference

12 September 2017

Shannon A Ferrante

series ordinal

1 reference

12 September 2017

Antoine C El Khoury

series ordinal

1 reference

12 September 2017

publication date

1 February 2013

1 reference

Applied Health Economics and Health Policy

12 September 2017

published in

1 reference

12 September 2017

1 reference

12 September 2017

1 reference

12 September 2017

page(s)

65-78

1 reference

Epidemiological aspects of hepatitis C in Portugal

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

Diagnosis, management, and treatment of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

New direct‐acting antivirals' combination for the treatment of chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

A New Era of Hepatitis C Therapy Begins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

Management of chronic hepatitis C patients who have relapsed or not responded to pegylated interferon alfa plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

Chronic hepatitis C treated with peginterferon alfa plus ribavirin in clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

Modeling for health care and other policy decisions: uses, roles, and validity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

Representing uncertainty: the role of cost-effectiveness acceptability curves

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

Boceprevir and telaprevir in the management of hepatitis C virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

Sustained Virologic Response to Antiviral Therapy for Chronic Hepatitis C Virus Infection: A Cure and So Much More

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

Effect of hepatitis C virus and its treatment on survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

Evidence for an association between the aetiology of cirrhosis and pattern of hepatocellular carcinoma development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

Determinants of outcome of compensated hepatitis C virus-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

Liver transplantation in the United States, 1999-2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

The burden of illness associated with hepatocellular carcinoma in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

Trends in organ donation and transplantation in the United States, 1999-2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

Health-State Utilities and Quality of Life in Hepatitis C Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

Cost Effectiveness of Peginterferon ??-2a Plus Ribavirin versus Interferon ??-2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-012-0007-8

10.1007/S40258-012-0007-8

21 January 2018

Identifiers

DOI

1 reference

12 September 2017

1 reference